Difference between revisions of "Mirtazapine-venlafaxine"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* '''Day 15:''' {{startVenla}}
 
* '''Day 15:''' {{startVenla}}
 
| caveat =  
 
| caveat =  
* Occurrence of serotonin syndrome is (not very likely) possible, so caution is necessary.}}
+
* Occurrence of serotonin syndrome is (not very likely) possible, so caution is necessary.
 +
 
 +
| info =
 +
{{review}}
 +
}}

Revision as of 14:24, 7 October 2015

Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine

Switch medication from mirtazapine to venlafaxine.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Day 1: reduce dosage of mirtazapine to a maximum of 30 mg/day.
  • Day 7: reduce to 15 mg/day.
  • Day 14: stop administration.
Eenrichtingbord.png Start venlafaxine
  • Day 15: Start administration of venlafaxine in a normal dosage of 37,5 mg or 75 mg (slow release) /day.
Letopbord.png Cave
  • Occurrence of serotonin syndrome is (not very likely) possible, so caution is necessary.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.